What is Infant Bacterial Therapeutics AB Earnings Yield (Joel Greenblatt) %?
Infant Bacterial Therapeutics AB's Enterprise Value for the quarter that ended in Mar. 2025 was kr466.97 Mil.
Infant Bacterial Therapeutics AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was kr-125.83 Mil. Infant Bacterial Therapeutics AB's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2025 was -26.95%.
The historical rank and industry rank for Infant Bacterial Therapeutics AB's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
OSTO:IBT B'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2086.06 Med: -6.81 Max: 930.9
Current: -27.29
During the past 11 years, the highest Earnings Yield (Joel Greenblatt) of Infant Bacterial Therapeutics AB was 930.90%. The lowest was -2086.06%. And the median was -6.81%.
OSTO:IBT B's Earnings Yield (Joel Greenblatt) % is ranked worse than 66.44% of 1347
companies
in the Biotechnology industry
Industry Median: -11.47
vs OSTO:IBT B: -27.29
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Infant Bacterial Therapeutics AB's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2025 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Infant Bacterial Therapeutics AB Earnings Yield (Joel Greenblatt) % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Infant Bacterial Therapeutics AB Earnings Yield (Joel Greenblatt) % Chart
For the Biotechnology subindustry, Infant Bacterial Therapeutics AB's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Infant Bacterial Therapeutics AB's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Infant Bacterial Therapeutics AB's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Infant Bacterial Therapeutics AB's Earnings Yield (Joel Greenblatt) % falls into.
Infant Bacterial Therapeutics AB Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Infant Bacterial Therapeutics AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-125.83 Mil.
Infant Bacterial Therapeutics AB (OSTO:IBT B) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Infant Bacterial Therapeutics AB Earnings Yield (Joel Greenblatt) % Related Terms
Thank you for viewing the detailed overview of Infant Bacterial Therapeutics AB's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.
Infant Bacterial Therapeutics AB Business Description
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OSTO:IBT B has been successfully added to your 